



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

产品名称: **Trilaciclib**
CAS 号: **1374743-00-6**
产品货号: **T27103**

生物活性:

Description	Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU chemotherapy[1].																								
IC50 & Target	IC50: 1 nM (CDK4), 4 nM (CDK6)[1]																								
In Vitro	与 Trilaciclib (G1T28) 孵育 24 小时可诱导强烈的 G1 细胞周期停滞 (时间=0)。Trilaciclib hydrochloride 清除后 16 小时, 细胞已重新进入细胞周期并表现出与未处理的对照细胞相似的细胞周期动力学。这些结果表明 Trilaciclib 引起短暂的、可逆的 G1 停滞。CDK4/6 敏感细胞中 Trilaciclib 介导的瞬时 G1 细胞周期停滞降低了多种与骨髓抑制相关的常用细胞毒性化疗药物的体外毒性[1]。 Cell Proliferation Assay[1] <table><tr><td>Cell Line:</td><td>HS68, WM2664 cells</td></tr><tr><td>Concentration:</td><td>300 nM</td></tr><tr><td>Incubation Time:</td><td>8h for measure 纬 H2AX foci (DNA damage); 48 hours to measure caspase 3/7 activity (apoptosis).</td></tr><tr><td>Result:</td><td>Produced a strong dose-dependent inhibition of HSPC proliferation within 12 hours. Elicited a robust dose-dependent decrease in caspase 3/7 activation suggesting an attenuation of apoptosis. Resulted a dose-dependent decrease in 纬 H2AX foci in all DNA damaging chemotherapies tested (carboplatin, doxorubicin, etoposide, camptothecin).</td></tr></table> Western Blot Analysis[1] <table><tr><td>Cell Line:</td><td>HS68, WM2664 cells</td></tr><tr><td>Concentration:</td><td>10, 30, 100, 300, 1000 nM</td></tr><tr><td>Incubation Time:</td><td>16 h</td></tr><tr><td>Result:</td><td>Blocked RB phosphorylation in the RB dependent cell lines by 16 hours post exposure, while the CDK4/6-independent cell line (A2058) exhibits no RB or pRB expression. Suggesting an attenuation of chemotherapy-induced DNA damag</td></tr></table> Cell Cycle Analysis[1] <table><tr><td>Cell Line:</td><td>HS68, WM2664 cells</td></tr><tr><td>Concentration:</td><td>300 nM</td></tr><tr><td>Incubation Time:</td><td>24 h</td></tr><tr><td>Result:</td><td>Inhibited only CDK4/6-dependent cells, with EC50 of 30 nM for HS68 cell. Singnificantly decreased the S phase cell numbers, increased the G1 phase cell numbers.</td></tr></table>	Cell Line:	HS68, WM2664 cells	Concentration:	300 nM	Incubation Time:	8h for measure 纬 H2AX foci (DNA damage); 48 hours to measure caspase 3/7 activity (apoptosis).	Result:	Produced a strong dose-dependent inhibition of HSPC proliferation within 12 hours. Elicited a robust dose-dependent decrease in caspase 3/7 activation suggesting an attenuation of apoptosis. Resulted a dose-dependent decrease in 纬 H2AX foci in all DNA damaging chemotherapies tested (carboplatin, doxorubicin, etoposide, camptothecin).	Cell Line:	HS68, WM2664 cells	Concentration:	10, 30, 100, 300, 1000 nM	Incubation Time:	16 h	Result:	Blocked RB phosphorylation in the RB dependent cell lines by 16 hours post exposure, while the CDK4/6-independent cell line (A2058) exhibits no RB or pRB expression. Suggesting an attenuation of chemotherapy-induced DNA damag	Cell Line:	HS68, WM2664 cells	Concentration:	300 nM	Incubation Time:	24 h	Result:	Inhibited only CDK4/6-dependent cells, with EC50 of 30 nM for HS68 cell. Singnificantly decreased the S phase cell numbers, increased the G1 phase cell numbers.
Cell Line:	HS68, WM2664 cells																								
Concentration:	300 nM																								
Incubation Time:	8h for measure 纬 H2AX foci (DNA damage); 48 hours to measure caspase 3/7 activity (apoptosis).																								
Result:	Produced a strong dose-dependent inhibition of HSPC proliferation within 12 hours. Elicited a robust dose-dependent decrease in caspase 3/7 activation suggesting an attenuation of apoptosis. Resulted a dose-dependent decrease in 纬 H2AX foci in all DNA damaging chemotherapies tested (carboplatin, doxorubicin, etoposide, camptothecin).																								
Cell Line:	HS68, WM2664 cells																								
Concentration:	10, 30, 100, 300, 1000 nM																								
Incubation Time:	16 h																								
Result:	Blocked RB phosphorylation in the RB dependent cell lines by 16 hours post exposure, while the CDK4/6-independent cell line (A2058) exhibits no RB or pRB expression. Suggesting an attenuation of chemotherapy-induced DNA damag																								
Cell Line:	HS68, WM2664 cells																								
Concentration:	300 nM																								
Incubation Time:	24 h																								
Result:	Inhibited only CDK4/6-dependent cells, with EC50 of 30 nM for HS68 cell. Singnificantly decreased the S phase cell numbers, increased the G1 phase cell numbers.																								
In Vivo	Trilaciclib (G1T28) 处理可在 12 小时内对 HSPC 的增殖产生强烈的剂量依赖性抑制, EdU 掺入在给																								



	药后 24 小时内以剂量依赖性方式恢复到接近基线水平。这些数据表明，单次口服剂量的 Trilaciclib 可以体内以剂量依赖性方式在 HSPC 中产生可逆的细胞周期停滞。在依托泊苷处理前 30 分钟给予 100 mg/kg Trilaciclib 的小鼠仅表现出背景水平的 caspase-3/7 活性。这些数据表明 Trilaciclib 可以在体内保护骨髓免受化疗诱导的细胞凋亡。数据表明，在 5-FU 之前使用 Trilaciclib 处理可能会减少 HSPC 中化疗引起的 5-FU 损伤，从而加速化疗后血细胞计数的恢复[1]。 <table><tr><td>Animal Model:</td><td>FVB/n female C57Bl6 mice[1]</td></tr><tr><td>Dosage:</td><td>50, 100, 150 mg/kg</td></tr><tr><td>Administration:</td><td>Po; single dose; treated followed 11 or 23 hours later by a single injection of EdU (100 µg; ip); mouse were euthanized 1 hour after EdU injection.</td></tr><tr><td>Result:</td><td>Showed a dose-dependent decrease in caspase 3/7 activation. Attenuated chemotherapy-induced myelosuppression in mice.</td></tr></table>					Animal Model:	FVB/n female C57Bl6 mice[1]	Dosage:	50, 100, 150 mg/kg	Administration:	Po; single dose; treated followed 11 or 23 hours later by a single injection of EdU (100 µg; ip); mouse were euthanized 1 hour after EdU injection.	Result:	Showed a dose-dependent decrease in caspase 3/7 activation. Attenuated chemotherapy-induced myelosuppression in mice.
Animal Model:	FVB/n female C57Bl6 mice[1]												
Dosage:	50, 100, 150 mg/kg												
Administration:	Po; single dose; treated followed 11 or 23 hours later by a single injection of EdU (100 µg; ip); mouse were euthanized 1 hour after EdU injection.												
Result:	Showed a dose-dependent decrease in caspase 3/7 activation. Attenuated chemotherapy-induced myelosuppression in mice.												
Solvent&Solubility	细胞实验: DMSO 中的溶解度 : 6.73 mg/mL (15.07 mM); ultrasonic and warming and adjust pH to 5 with 1 M HCl and heat to 60°C; 吸湿的 DMSO 对产品的溶解度有显著影响, 请使用新开封的 DMSO)												
	Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg								
		1 mM	2.2394 mL	11.1970 mL	22.3939 mL								
		5 mM	0.4479 mL	2.2394 mL	4.4788 mL								
		10 mM	0.2239 mL	1.1197 mL	2.2394 mL								
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 动物实验: 以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。 方案 一 请依序添加每种溶剂： 50% PEG300 → 50% Saline Solubility: 10 mg/mL (22.39 mM); 悬浊液；超声助溶 方案 二 请依序添加每种溶剂： 0.5% CMC-Na/1% Tween-80 in Saline water Solubility: 9.9 mg/mL (22.17 mM); 悬浊液；超声助溶													
参考文献	[1]. Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93.												
	完整储备液配制表: * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。												
可选溶剂	质量 / 溶剂体积 / 浓度	1 mg	5 mg	10 mg	25 mg								



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

DMSO	1 mM	2.2394 mL	11.1970 mL	22.3939 mL	55.9848 mL
	5 mM	0.4479 mL	2.2394 mL	4.4788 mL	11.1970 mL
	10 mM	0.2239 mL	1.1197 mL	2.2394 mL	5.5985 mL
	15 mM	0.1493 mL	0.7465 mL	1.4929 mL	3.7323 mL



源叶